Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
about
Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI studyComparison of the effects of eldecalcitol with either raloxifene or bisphosphonate on serum tartrate resistant acid phosphatase-5b, a bone resorption marker, in postmenopausal osteoporosis.Localization of Minodronate in Mouse Femora Through Isotope MicroscopyNumber and severity of prevalent vertebral fractures and the risk of subsequent vertebral fractures in Japanese women with osteoporosis: results from the minodronate trial.Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene.A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis.Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors.Changes of bone mineral density and serum pentosidine during a 27-month follow-up of monthly minodronate in osteoporotic patients.Evaluation of crystallographic orientation of biological apatite in vertebral cortical bone in ovariectomized cynomolgus monkeys treated with minodronic acid and alendronate.The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.Minodronate for the treatment of osteoporosis.Efficacy of Switching From Teriparatide to Bisphosphonate or Denosumab: A Prospective, Randomized, Open-Label Trial
P2860
Q34051900-8C54DABB-41EE-4A83-AA96-8CB06ACB7F4BQ36908916-BF2056DD-6E60-47D2-9B04-DB00A53E55CCQ41648438-B6435966-6C4A-418C-8020-CC21F9F000C0Q43771659-C05CBB0A-BC45-4FBF-B001-89C458B1D4ABQ45341149-0DE8D38D-8288-4CF5-AE4D-B27B04996772Q47696114-FCA68913-EF0D-4122-B9BB-612D76E5BA95Q48128891-D9486EE0-44DA-42A0-9D96-F01A26894921Q50184850-B9418067-9591-4BCE-BB94-18159A10058BQ50789280-2EAC7255-2E40-4E87-A139-9623F656A17DQ51037431-27E6EE76-5E3F-49A8-9092-2D30B0FAE676Q52613909-6FF96AEB-F0C1-46A7-B8D4-74D3CF47C773Q55077666-F67CDA88-EEB2-49F0-A9FB-E3716B152C68Q57144512-F9E5CE52-9AF0-4514-BFB8-232455BC82AE
P2860
Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
@ast
Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
@en
type
label
Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
@ast
Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
@en
prefLabel
Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
@ast
Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
@en
P2093
P2860
P1476
Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
@en
P2093
Hiroshi Hagino
Kunio Takaoka
Masao Fukunaga
Masataka Shiraki
Tetsuo Nakano
Toshio Matsumoto
Toshitaka Nakamura
Yasuo Ohashi
P2860
P2888
P304
P356
10.1007/S00774-011-0332-2
P577
2011-12-02T00:00:00Z